38 results about "Carbocyclic nucleoside" patented technology

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Hepatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses.

The invention relates to a preparation method and a purpose of a novel nucleoside phosphoramidic acid / phosphonate prodrug simultaneously formed by alkoxide benzyl alcohol and D or L-amino-acid ester. The novel nucleoside phosphoramidic acid / phosphonate prodrug containing alkoxide benzyl is a compound shown by the formula (I) or an isomer or a medicinal salt of the compound. The compound can be used as prodrug of various nucleoside analogs such as acyclic nucleoside, carbocyclic nucleoside and furan ring nucleoside; the bioactivity of the nucleoside compounds are enhanced, so that the application of the compound in the fields of virus infection and cancer treatment is optimized. The formula is shown in the description.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Hepatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses, especially HBV.

The invention relates to (-)-[gamma]-lactamase, a gene and a mutant of the (-)-[gamma]-lactamase, a recombinant expression plasmid and a recombinant expression transformant containing the gene and the mutant, a preparation method of the (-)-[gamma]-lactamase and an application of the (-)-[gamma]-lactamase in preparing (+)-[gamma]-lactam. Compared with the prior art, the (-)-[gamma]-lactamase disclosed by the invention has the characteristics of being high in enzymatic activity and good in substrate concentration tolerance; the (+)-[gamma]-lactam, which is prepared through enzymatic catalysis, has the advantages of being mild in reaction condition, high in substrate concentration, low in catalyst dosage and the like; therefore, the (-)-[gamma]-lactamase has a good application prospect in industrial production of the (-)-[gamma]-lactamase which is an intermediate product of carbocyclic nucleoside drugs.

Enantiomers of 1′,6′-isoneplanocin, including derivatives of the enantiomers of 1′,6′-isoneplanocin, are disclosed along with novel synthetic methods. In particular, a substituted cyclopentane epoxide is synthesized into the enantiomers of 1′,6′-isoneplanocin. Enantiomers of carbocyclic nucleoside analogs of 3-deazaneplanocin to provide D- and L-like 1′,6′-iso-3-deazaneplanocin are also disclosed. The small molecule chemotherapeutic compounds beneficially provide DNA and RNA antiviral activity, demonstrating activity towards, for example, human cytomegalovirus, measles, Ebola, norovirus, dengue, vaccinia and HBV. Compounds exhibiting reduced S-adenosylhomocysteine hydrolase inhibitory effects are disclosed and provide improved toxicity profiles in comparison to neplanocin. The invention provides improved prophylactic and / or therapeutic antiviral efficacy.

Disclosed are compounds of the formula Iand the pharmaceutically acceptable salts of such compounds. Also disclosed are processes for the preparation of such compounds, intermediates used in the preparation of such compounds, and the uses of such compounds in treating inflammatory skin diseases.

The invention discloses a method for synthesizing chiral five-membered carbon ring purine nucleoside through [3+2] cycloaddition based on allenoates and belongs to the field of asymmetric synthesis inorganic chemistry. The method takes alpha-purine substituted acrylate 1 and allenoates 2 as raw materials, and chiral STICP as a catalyst; after the raw materials and the catalyst react, chiral five-membered carbon ring nucleoside 3 is obtained; reaction has good enantioselectivity and has moderate to excellent yield. Chiral five-membered carbon ring nucleoside 3 is reduced under the condition ofsodium borohydride to obtain mono-alcohol five-membered carbon ring purine nucleoside 4; then mono-alcohol five-membered carbon ring purine nucleoside 4 is reduced by adopting DIBAL-H to obtain diolfive-membered carbon ring purine nucleoside 5.

The invention discloses a method for synthesizing three-membered carbocyclic nucleosides substituted by 2'-spirocyclic groups, belonging to the technical field of organic chemistry. Using α-pyrimidine-substituted acrylate and α-chlorocycloalkanone as raw materials, a series of novel spirocyclic nucleosides were synthesized through the cyclopropanization reaction initiated by the Mike reaction. The invention adopts simple and easy-to-obtain raw materials, and avoids the shortcomings of many steps, low yield and poor universality in the previous methods in the synthesis process. The yield of the spirocyclic pyrimidine nucleoside synthesized by this method is as high as 84%, and the product structure is rich.

The disclosed six-membered carbocyclic nucleoside analogues comprise: adenosine analogue, guanosine analogue, carnine analogue, mercaptopurine riboside analogue, cytidine analogue, 5-fluorocytidine analogue, uridine analogue, 5-fluorouridine analogue, and thymidine analogue as well as their acceptable salts formed by equimolar acid in pharmacy. Wherein, the opposite five-step synthesis method using the pinitol, acetone, methane sulfonyl chloride, p-toluenesulfonyl chloride, benzene sulfochloride, and nucleoside base as materials; the pyridine, water, glacial acetic acid, absolute methanol, DMSO, N, N-DMF as the solvent; the p-toluenesulfonic acid, 2, 2-dimethoxylpropane, anhydrous NaSO4, NaHCO3, triethylamine, and anhydrous K2CO3 as the catalyst. This invention restrains specially the replication of HIV and herpesvirus.

The invention discloses a synthesis method of 5-formamidoimidazole-4-carboxamide ribotide analogue. The analysis method comprises the following steps: by taking (3aR,4S,6R,6aS)-methyl-6-amino-2,2-dimethyltetrahydro-3ahydro-cyclo[d][1,3]dioxo-4-carboxylate, triethyl orthoformate and 2-amino-2-cyanoacetamide as raw materials, conducting loop closing through reflux reaction to obtain an intermediate, reducing with lithium borohydride, reacting with phosphorus oxychloride, and then hydrolyzing to obtain the 5-formamidoimidazole-4-carboxamide ribotide analogue. In the mode, the synthesis method of the 5-formamidoimidazole-4-carboxamide ribotide analogue comprises few reaction steps, is mild in reaction conditions, convenient in refining, simple to carry out, high in reaction quality, high in yield, and good in environment friendliness.

The present invention is directed carbocyclic nucleoside reverse transcriptase inhibitors compounds of Formula Iand their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and / or ARC.

The invention discloses a chiral tri-carbocyclic pyrimidine nucleoside analogue and a preparation method of the chiral tri-carbocyclic pyrimidine nucleoside analogue. The preparation method comprises the following steps of taking dioxane as a solvent, adding Ru-pheox as a ligand and a catalyst, then adding an ethyl diazoacetate reactant, stirring at a room temperature for 4 minutes, and reacting at the room temperature. The preparation method disclosed by the invention is a simple, convenient, green and efficient method for synthesizing the chiral tri-carbocyclic pyrimidine nucleoside analogue, aims to solve the problems of expensive raw materials and complicated process in the process of synthesizing the kind of compound, and has the advantages that a reference value is provided for the synthesis and application of nucleoside drugs, and the raw material is provided for the research of new antiviral drugs and new antitumor drugs.

The invention discloses a novel benzyl amido phosphate structure shown as a formula (I). The novel benzyl amido phosphate ester structure can be taken as a prodrug of various nucleoside compounds (including acyclic nucleoside, carbocycle nucleoside, furan ring nucleoside and the like) for enhancing the bioactivity of the nucleoside compounds, so that the novel benzyl amido phosphate ester structure is applied to treatment of virus infection and cancers.

The invention relates to a method for synthesizing five-membered carbocyclic nucleoside, comprising the following steps of: 1) synthesizing a compound 26 in the reaction equation 1, and oxidizing the compound 26 into a dicarbonyl compound 34 by the use of a TEMPO-NaClO system; 2) carrying out selective protection on ketone carbonyl in the compound 34 to generate a compound 35; 3) reducing ketone carbonyl in the compound 35 into a compound 36 with a terminal containing a double bond; 4) performing an addition reaction between the compound 36 and hydrogen bromide by anti-Markovnikov's rule to obtain a bromide 37; and 5) carrying out lithium halogen exchange on the compound 37 to generate nucleophilic addition cyclization within the molecules so as to obtain a compound 38, namely five-membered ring carbasugars; and performing a routine reaction to obtain the five-membered carbocyclic nucleoside. By the adoption of the method provided by the invention, the yield of the five-membered ring carbasugars is greatly raised, and simultaneously usage frequency of extreme low temperature reaction is minimized. All the raw materials used are cheap and easily available.